# Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

Source: https://onco.cc/trials/nct06079671/  
OnCo record `nct06079671` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Volrustomig in cervical cancer, run by AstraZeneca, now recruiting.

## Summary

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) is a phase 3 interventional study registered as NCT06079671 by AstraZeneca, with 800 participants planned, started 2023-09-22 and due to reach its primary completion in 2027-11-26. Interventions recorded: Volrustomig.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06079671
- Phase: 3
- Setting: A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)
- Sponsor: AstraZeneca
- Enrolled: 800

## Sources

- ClinicalTrials.gov NCT06079671: https://clinicaltrials.gov/study/NCT06079671

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06079671.json